Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High - Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) reached a new 52-week high during trading on Wednesday . The company traded as high as $4.68 and last traded at $4.39, with a volume of 4430709 shares traded. The stock had previously closed at $4.59.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on XERS shares. Craig Hallum raised their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Leerink Partners raised their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Piper Sandler reiterated a "neutral" rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Xeris Biopharma currently has an average rating of "Moderate Buy" and a consensus price target of $5.92.

Xeris Biopharma Price Performance

The company has a market capitalization of $654.47 million, a price-to-earnings ratio of -9.76 and a beta of 2.32. The firm has a 50-day moving average price of $3.61 and a two-hundred day moving average price of $3.28.

Hedge Funds Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of XERS. Legato Capital Management LLC bought a new stake in Xeris Biopharma in the 4th quarter valued at about $482,000. Barclays PLC increased its holdings in Xeris Biopharma by 87.8% in the 3rd quarter. Barclays PLC now owns 324,472 shares of the company's stock valued at $925,000 after buying an additional 151,685 shares during the period. Geode Capital Management LLC raised its position in shares of Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after buying an additional 93,091 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of Xeris Biopharma by 30.3% in the 3rd quarter. Principal Financial Group Inc. now owns 102,469 shares of the company's stock valued at $292,000 after buying an additional 23,843 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Xeris Biopharma during the 3rd quarter worth approximately $44,000. Institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads